Kenneth Hoberman Insider Profile

4 Followers
Kenneth Hoberman, COO at Stemline Therapeutics, holds 264.94K shares in TG Therapeutics (Ticker: TGTX), holds 103.14K shares in Nuvectis Pharma (Ticker: NVCT), holds 0.00 shares in Stemline Therapeutics (Ticker: STML).
tipranks
Kenneth Hoberman

Kenneth Hoberman
Stemline Therapeutics (STML)
COO

Ranked #52,997 out of 99,218 Corporate Insiders

Profitable Transactions

70%
16 out of 23 Profitable Transactions

Average Return

-0.90%
Average return per transaction
Time Frame
1 Year
Compare to
No Benchmark

Insider Holdings

$8M
89.94%
10.06%
A breakdown of Kenneth Hoberman's holdings

Insider Roles

TG Therapeutics
(TGTX)
Director
Nuvectis Pharma
(NVCT)
Director
Roles that Kenneth Hoberman holds in companies

Most Profitable Insider Trade

Stock:
Stemline Therapeutics
(STML)
Rating:Informative Sell
Date:Feb 20, 2015 - Feb 20, 2016
Return:+70.20%
The most profitable trade made by Kenneth Hoberman

Kenneth Hoberman's Trading History

Company Name
Last Transaction Date
Insider Position
Last Transaction
Last Transaction Amount
Holding Value
STML
Stemline Therapeutics
Jun 10, 2020
Uninformative Buy
$0.00
Nuvectis Pharma
Jun 13, 2024
Director
Uninformative Buy
$766.33K
TG Therapeutics
Jun 20, 2024
Director
Uninformative Buy
$6.85M
List of latest transactions for each holding click on a transaction to see Kenneth Hoberman's performance on stock

Kenneth Hoberman insider profile FAQ

What is the percentage of profitable transactions made by Kenneth Hoberman?
The percentage of profitable transactions made by Kenneth Hoberman is 70%.
    What is the average return per transaction made by Kenneth Hoberman?
    The average return per transaction made by Kenneth Hoberman is -0.90%.
      What stocks does Kenneth Hoberman hold?
      Kenneth Hoberman holds: STML, NVCT, TGTX stocks.
        What was Kenneth Hoberman’s latest transaction?
        Kenneth Hoberman latest transaction was an Uninformative Buy of ―.
          What was Kenneth Hoberman's most profitable transaction?
          Kenneth Hoberman’s most profitable transaction was an Informative Sell of STML stock on February 20, 2015. The return on the trade was 70.20%.
            What is Kenneth Hoberman's role in Stemline Therapeutics?
            Kenneth Hoberman's role in Stemline Therapeutics is COO.
              How can I follow the stock ratings of top corporate insiders?
              Head over to our Expert Center to see a list of the Top 100 corporate insiders and follow the corporate insiders of your choice. Visit their profiles for more details about their stock transactions and see how they perform on a stock-by-stock basis.